ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 526

Comparative Pulmonary Safety of Abatacept and Tumor Necrosis Factor Inhibitors in Patients with RA and Chronic Pulmonary Condition

Eun Ha Kang1, Yinzhu Jin2, Sara Dejene3, Gregory Brill3, Rishi J. Desai2, Jeffrey A. Sparks4 and Seoyoung C. Kim5, 1Division of Rheumatology, Department of Internal Medicine, Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea, Republic of (South), 2Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, MA, 3Brigham and Women's Hospital, Boston, MA, 4Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 5Rheumatology, Immunology and Allergy; Pharmacoepidemiologyand Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Abatacept, pulmonary complications, Rheumatoid arthritis (RA), safety and tumor necrosis factor (TNF)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 5, 2017

Session Title: Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster I: Comorbidities and Adverse Events; Efficacy and Safety of Small Molecules

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Patients with rheumatoid arthritis (RA) can have various pulmonary comorbidities including asthma, chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD). Biologics can pose a potential risk for acute exacerbations (AE) of these pulmonary comorbidities by immunosuppression, drug-induced lung injury, or other mechanisms. We therefore compared the risk of pulmonary AE among RA patients initiating abatacept vs. TNF inhibitors (TNFi) with chronic pulmonary comorbidities at baseline.

Methods: We conducted a cohort study using claims data from Medicare (2008-2013) or a commercial health plan (MarketScan 2006-6/2015) in the US. Adults with RA and chronic pulmonary condition (i.e., asthma, COPD, or ILD) who initiated abatacept or TNFi were identified based on a combination of diagnosis codes and use of disease-specific medications. The cohort entry date was the 1st use of abatacept or TNFi after ≥12 month continuous enrollment. The primary outcome was a composite endpoint defined as any of: 1) inpatient stays or 2) ED visits for asthma, COPD, or ILD, or 3) outpatient visits for asthma, COPD or ILD plus dispensing of oral corticosteroids or antibiotics, or for respiratory complications such as pneumonitis and bronchitis. Secondary outcomes were individual components of the primary composite endpoint. Follow-up time started from the day after cohort entry to the earliest event of outcome occurrence, drug discontinuation, nursing home admission, disenrollment, end of study period, or death. To control for >50 potential confounders at baseline, abatacept initiators were matched to TNFi initiators on a propensity score (PS) with a 1:2 ratio in each of the three pulmonary condition subgroups. We estimated incidence rates (IR) and hazard ratios (HR) of the outcomes among abatacept initiators versus TNFi in the main cohort and the subgroups. PS-matched HRs from the two databases were then pooled using inverse variance-weighted fixed-effect method.

Results: After PS matching, we included 1,517 abatacept and 3,034 TNFi initiators with RA and chronic pulmonary condition from both databases. Mean (SD) age was 73.0 (6.1) years in Medicare and 61.2 (12.1) years in MarketScan. At baseline, 44% in MarketScan and 57% in Medicare used methotrexate. IR of the composite outcome per 100 person-years ranged from 47.6-49.6 in the abatacept group and from 51.8-53.5 in the TNFi group. For the primary composite outcome, the HR comparing abatacept to TNFi was 1.00 (95%CI 0.92-1.09) in Medicare and 1.00 (95%CI 0.89-1.12) in MarketScan with a pooled HR of 1.00 (95%CI 0.93-1.07). Secondary and subgroup analyses showed similar results (Figure).  

Conclusion:  Among patients with RA and chronic pulmonary condition, acute exacerbations of underlying asthma, COPD or ILD occurred frequently but we found no difference in the exacerbation risk between abatacept and TNFi initiators.

BMS aim 3_forest plot_v2.png

 

 


Disclosure: E. H. Kang, None; Y. Jin, None; S. Dejene, None; G. Brill, None; R. J. Desai, None; J. A. Sparks, None; S. C. Kim, BMS, 2,Roche Pharmaceuticals, 2,AstraZeneca, 2,Pfizer Inc, 2,Merck Pharmaceuticals, 2.

To cite this abstract in AMA style:

Kang EH, Jin Y, Dejene S, Brill G, Desai RJ, Sparks JA, Kim SC. Comparative Pulmonary Safety of Abatacept and Tumor Necrosis Factor Inhibitors in Patients with RA and Chronic Pulmonary Condition [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/comparative-pulmonary-safety-of-abatacept-and-tumor-necrosis-factor-inhibitors-in-patients-with-ra-and-chronic-pulmonary-condition/. Accessed June 29, 2022.
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparative-pulmonary-safety-of-abatacept-and-tumor-necrosis-factor-inhibitors-in-patients-with-ra-and-chronic-pulmonary-condition/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies